88 related articles for article (PubMed ID: 14534923)
1. Is FDG-PET a useful tool in clinical practice for diagnosing corticobasal ganglionic degeneration?
Coulier IM; de Vries JJ; Leenders KL
Mov Disord; 2003 Oct; 18(10):1175-8. PubMed ID: 14534923
[TBL] [Abstract][Full Text] [Related]
2. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography.
Eidelberg D; Dhawan V; Moeller JR; Sidtis JJ; Ginos JZ; Strother SC; Cederbaum J; Greene P; Fahn S; Powers JM
J Neurol Neurosurg Psychiatry; 1991 Oct; 54(10):856-62. PubMed ID: 1744638
[TBL] [Abstract][Full Text] [Related]
3. FDG PET in the differential diagnosis of parkinsonian disorders.
Eckert T; Barnes A; Dhawan V; Frucht S; Gordon MF; Feigin AS; Eidelberg D
Neuroimage; 2005 Jul; 26(3):912-21. PubMed ID: 15955501
[TBL] [Abstract][Full Text] [Related]
4. Multitracer study with positron emission tomography in Creutzfeldt-Jakob disease.
Engler H; Lundberg PO; Ekbom K; Nennesmo I; Nilsson A; Bergström M; Tsukada H; Hartvig P; Långström B
Eur J Nucl Med Mol Imaging; 2003 Jan; 30(1):85-95. PubMed ID: 12483414
[TBL] [Abstract][Full Text] [Related]
5. Significance of incidental fluorodeoxyglucose uptake in the parotid glands and its impact on patient management.
Basu S; Houseni M; Alavi A
Nucl Med Commun; 2008 Apr; 29(4):367-73. PubMed ID: 18317302
[TBL] [Abstract][Full Text] [Related]
6. Positron emission tomography with [(18)F]FDG in the diagnosis of Creutzfeldt-Jakob disease (CJD).
Henkel K; Zerr I; Hertel A; Gratz KF; Schröter A; Tschampa HJ; Bihl H; Büll U; Grünwald F; Drzezga A; Spitz J; Poser S
J Neurol; 2002 Jun; 249(6):699-705. PubMed ID: 12111302
[TBL] [Abstract][Full Text] [Related]
7. Imaging of activated microglia with PET and [11C]PK 11195 in corticobasal degeneration.
Henkel K; Karitzky J; Schmid M; Mader I; Glatting G; Unger JW; Neumaier B; Ludolph AC; Reske SN; Landwehrmeyer GB
Mov Disord; 2004 Jul; 19(7):817-821. PubMed ID: 15254941
[TBL] [Abstract][Full Text] [Related]
8. PET study of cerebral glucose metabolism and fluorodopa uptake in patients with corticobasal degeneration.
Nagasawa H; Tanji H; Nomura H; Saito H; Itoyama Y; Kimura I; Tuji S; Fujiwara T; Iwata R; Itoh M; Ido T
J Neurol Sci; 1996 Aug; 139(2):210-7. PubMed ID: 8856655
[TBL] [Abstract][Full Text] [Related]
9. Dementia as the most common presentation of cortical-basal ganglionic degeneration.
Grimes DA; Lang AE; Bergeron CB
Neurology; 1999 Dec; 53(9):1969-74. PubMed ID: 10599767
[TBL] [Abstract][Full Text] [Related]
10. Imaging of oncologic patients: benefit of combined CT and FDG PET in the diagnosis of malignancy.
Eubank WB; Mankoff DA; Schmiedl UP; Winter TC; Fisher ER; Olshen AB; Graham MM; Eary JF
AJR Am J Roentgenol; 1998 Oct; 171(4):1103-10. PubMed ID: 9763005
[TBL] [Abstract][Full Text] [Related]
11. Uncoupling of fatty acid and glucose metabolism in malignant lymphoma: a PET study.
Nuutinen J; Minn H; Bergman J; Haaparanta M; Ruotasalainen U; Laine H; Knuuti J
Br J Cancer; 1999 May; 80(3-4):513-8. PubMed ID: 10408861
[TBL] [Abstract][Full Text] [Related]
12. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
[TBL] [Abstract][Full Text] [Related]
13. [Clinical usefulness of FDG-PET in oncology].
Sasaki M
Nihon Igaku Hoshasen Gakkai Zasshi; 2001 Jul; 61(8):414-20. PubMed ID: 11524817
[TBL] [Abstract][Full Text] [Related]
14. 18-fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas.
Sperti C; Bissoli S; Pasquali C; Frison L; Liessi G; Chierichetti F; Pedrazzoli S
Ann Surg; 2007 Dec; 246(6):932-7; discussion 937-9. PubMed ID: 18043094
[TBL] [Abstract][Full Text] [Related]
15. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias.
Koeppe RA; Gilman S; Joshi A; Liu S; Little R; Junck L; Heumann M; Frey KA; Albin RL
J Nucl Med; 2005 Jun; 46(6):936-44. PubMed ID: 15937303
[TBL] [Abstract][Full Text] [Related]
16. [¹⁸F]FDG-PET is superior to [¹²³I]IBZM-SPECT for the differential diagnosis of parkinsonism.
Hellwig S; Amtage F; Kreft A; Buchert R; Winz OH; Vach W; Spehl TS; Rijntjes M; Hellwig B; Weiller C; Winkler C; Weber WA; Tüscher O; Meyer PT
Neurology; 2012 Sep; 79(13):1314-22. PubMed ID: 22914831
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG hybrid PET in patients with suspected spondylitis.
Gratz S; Dörner J; Fischer U; Behr TM; Béhé M; Altenvoerde G; Meller J; Grabbe E; Becker W
Eur J Nucl Med Mol Imaging; 2002 Apr; 29(4):516-24. PubMed ID: 11914890
[TBL] [Abstract][Full Text] [Related]
18. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation.
Anderson GS; Brinkmann F; Soulen MC; Alavi A; Zhuang H
Clin Nucl Med; 2003 Mar; 28(3):192-7. PubMed ID: 12592125
[TBL] [Abstract][Full Text] [Related]
19. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes.
Younes-Mhenni S; Janier MF; Cinotti L; Antoine JC; Tronc F; Cottin V; Ternamian PJ; Trouillas P; Honnorat J
Brain; 2004 Oct; 127(Pt 10):2331-8. PubMed ID: 15361417
[TBL] [Abstract][Full Text] [Related]
20. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.
Kostakoglu L; Leonard JP; Kuji I; Coleman M; Vallabhajosula S; Goldsmith SJ
Cancer; 2002 Feb; 94(4):879-88. PubMed ID: 11920454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
